VolitionRx's Nu.Q® Cancer Assays Take a Major Step Towards Clinical Use

VolitionRx Takes a Leap in Cancer Diagnostics with Nu.Q® Assays

In a significant milestone for cancer detection, VolitionRx Limited (NYSE AMERICAN: VNRX), an innovative epigenetics firm, has completed its first sale of the highly anticipated Nu.Q® Cancer assays. This groundbreaking event occurred at the Hospices Civils de Lyon, one of Europe's premier cancer centers, located in Lyon, France. The announcement, made on November 25, 2025, highlights Volition's commitment to revolutionizing cancer diagnostics through advanced technology.

Professor Léa Payen, a Toxicology and Biochemistry expert from Claude Bernard University of Lyon I, shared her enthusiasm, stating, “We are excited to place this first order of Nu.Q® Cancer assays to finalize our internal certification, getting us ready to integrate this test into our clinical practice for cancer management.” This partnership reflects years of collaboration with VolitionRx, focusing on developing compelling scientific and clinical evidence to support the use of Nu.Q® for cancer patient management.

The Nu.Q® Cancer assays are designed to measure levels of methylated nucleosome biomarkers in patients diagnosed with Non-Small Cell Lung Cancer (NSCLC). According to the research conducted by the Lyon team, these biomarkers provide critical insights into survival rates, progression-free survival, and notably, they enhance the detection of patients eligible for potentially curative treatments. The implications of this technology are vast, positioning clinicians to make more informed treatment decisions tailored to individual patient needs.

Dr. Andrew Retter, Chief Medical Officer of VolitionRx, emphasized the importance of this advancement, saying, “Nu.Q® Cancer technology equips healthcare professionals with enhanced tools for clinical prognostication. By improving treatment pathways for individual patients, we aim to boost overall survival rates and ensure care is centered around patient needs.” The technology underpins the company's ethos of precision medicine, striving for more effective cancer treatment and monitoring, thus heralding a new era in patient care.

The milestones achieved through this collaboration are only the beginning. Gael Forterre, Volition's Chief Commercial Officer, declared, “This achievement is pivotal for our efforts in commercializing Nu.Q®. We’re enthusiastically anticipating the integration of our technology into routine clinical practice, which aligns with Volition’s mission to use our innovations to save lives.”

VolitionRx is dedicated to advancing the field of epigenetics. The company is not only focused on cancer detection but also on developing accessible, blood-based tests to monitor a variety of diseases, including sepsis and other health conditions linked to NETosis. This work aims to enhance early detection and ultimately improve patient quality of life.

Headquartered in Belgium, with operational laboratories in the U.S. and an office in London, Volition continues to push the boundaries of diagnostics. The exciting partnership with the Hospices Civils de Lyon serves as both a testament to the efficacy of their technology and as a beacon of hope for patients in need of life-saving diagnostic tools.

As VolitionRx moves forward, the anticipation builds around further developments and commercial opportunities for Nu.Q® Cancer assays, poised to transform cancer diagnostics and patient care practices on a wider scale. The combination of academic collaboration and innovative technology promises to enhance the ability for clinicians to provide exceptional care and improve treatment outcomes for patients dealing with cancer.

For those interested in the forefront of cancer diagnostics, this news from VolitionRx is certainly one to follow, as it has the potential to change the landscape for how cancer is managed in clinical settings worldwide.